What Does the Research Say About Ozempic Side Effects?

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Science to Targeted Drug Safety

If you're taking Ozempic and experiencing persistent nausea, vomiting, or abdominal pain, you may be concerned about serious gastrointestinal side effects. The medical community has a long tradition of systematically collecting and analyzing clinical data to improve patient safety—a heritage that now extends to evaluating adverse events associated with GLP-1 receptor agonists like Ozempic. This page reviews the published research on recognized side effects, including gastroparesis, and outlines what monitoring and reporting guidelines suggest for patients and healthcare providers.

Understanding Gastroparesis and Its Clinical Diagnosis

Gastroparesis is a disorder characterized by delayed gastric emptying in the absence of mechanical obstruction, leading to symptoms such as nausea, vomiting, early satiety, bloating, and abdominal pain. Clinical diagnosis typically involves gastric emptying scintigraphy, where a delay in the emptying of a radiolabeled meal confirms the condition. The clinical presentation can overlap with common gastrointestinal complaints, making diagnosis challenging without objective testing. This section bridges the legacy of general health science with the specific medical context of Ozempic-associated gastroparesis, emphasizing the importance of accurate diagnosis in the context of potential drug-induced injury.

Ozempic and Gastrointestinal Adverse Reactions: Evidence from Clinical Trials

Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for the management of type 2 diabetes mellitus. Its pharmacology includes slowing gastric emptying as part of its mechanism to reduce postprandial glucose excursions. This effect, while therapeutic for glycemic control, can contribute to gastrointestinal adverse reactions. In placebo-controlled trials, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo (placebo 15.3%, Ozempic 0.5 mg 32.7%, Ozempic 1 mg 36.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). More patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial with Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic 2 mg (34.0%) vs Ozempic 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Specific adverse reactions reported in ≥5% of Ozempic-treated patients included nausea (15.8% for 0.5 mg, 20.3% for 1 mg), vomiting (5.0% for 0.5 mg, 9.2% for 1 mg), diarrhea (8.5% for 0.5 mg, 8.8% for 1 mg), abdominal pain (7.3% for 0.5 mg, 5.7% for 1 mg), and constipation (5.0% for 0.5 mg, 3.1% for 1 mg) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

Mechanistic Link Between Ozempic and Gastroparesis

The mechanistic pathway linking Ozempic to gastroparesis involves the drug's effect on gastric motility. GLP-1 receptor agonists slow gastric emptying by inhibiting vagal nerve activity and relaxing the gastric fundus, which can lead to delayed gastric emptying and symptoms consistent with gastroparesis. While the prescribing information for Ozempic does not explicitly list gastroparesis as a warning, the high incidence of gastrointestinal adverse reactions and the drug's known effect on gastric motility raise concerns about the adequacy of warnings regarding this potential harm. The label includes a warning for serious hypersensitivity reactions such as anaphylaxis and angioedema (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166), but does not specifically address the risk of gastroparesis. This gap in labeling may affect the adequacy of warnings for patients who develop gastroparesis after using Ozempic.

Statute of Limitations for Ozempic Claims in Illinois

For affected patients in Illinois considering a settlement related to Ozempic-associated gastroparesis, the statute of limitations is a critical factor. In Illinois, personal injury claims generally must be filed within two years from the date the injury was discovered or should have been discovered through reasonable diligence. This timeline is governed by 735 ILCS 5/13-202. The 'discovery rule' means the clock starts when the patient knew or should have known that Ozempic caused their gastroparesis. Given that gastroparesis symptoms can develop gradually and may be initially attributed to other causes, the timeline between exposure and documented harm is important. Patients who used Ozempic and later developed persistent nausea, vomiting, or abdominal pain should seek medical evaluation for gastroparesis. If diagnosed, the date of diagnosis or the date when a causal link to Ozempic was reasonably suspected may trigger the statute of limitations. Settlement-related considerations for affected patients include documenting the timeline of Ozempic use, onset of symptoms, and medical diagnosis. Evidence of gastrointestinal adverse reactions during dose escalation, as noted in clinical trials, may support a claim that the drug contributed to the condition. However, the absence of a specific warning for gastroparesis in the label could be a factor in evaluating the manufacturer's liability. Patients should consult with a legal professional experienced in pharmaceutical litigation to assess their individual circumstances and ensure compliance with Illinois' statute of limitations.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Ozempic gastroparesis claims in Illinois?

In Illinois, personal injury claims generally must be filed within two years from the date the injury was discovered or should have been discovered through reasonable diligence, as per 735 ILCS 5/13-202. The discovery rule means the clock starts when the patient knew or should have known that Ozempic caused their gastroparesis.

How does Ozempic cause gastroparesis?

Ozempic (semaglutide) slows gastric emptying by inhibiting vagal nerve activity and relaxing the gastric fundus, which can lead to delayed gastric emptying and symptoms consistent with gastroparesis. Clinical trials show high rates of gastrointestinal adverse reactions, including nausea, vomiting, and abdominal pain (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

DailyMed - Ozempic Prescribing Information

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.